Onconic Therapeutics 2026 Q1 Strong Performance: Revenue Surge and Sustained Profitability

Consolidated revenue of KRW 22.98B in Q1 2026, up 150.6% YoY from KRW 9.17B
Operating profit KRW 4.59B, net profit KRW 6.42B, significantly improved from KRW 1.54B and KRW 1.88B respectively in Q1 2025 (up 197% and 242% YoY)
Cash and cash equivalents KRW 51.77B, debt-free (total borrowings 0)
Total equity KRW 79.52B, up 10.4% from previous year-end KRW 72.04B
Strong domestic sales of flagship product Zastaprazan (P-CAB) for erosive esophagitis and gastric ulcer; Phase 3 trials ongoing for additional indications (NSAID-induced ulcer prevention, non-erosive reflux disease)
Nesuparib (PARP/TNKS dual inhibitor) holds 4 FDA Orphan Drug Designations (pancreatic, gastric, SCLC - latest Feb 2026); multiple domestic Phase 2 trials underway
License-out deals for Zastaprazan in Greater China (Livzon), India, and 19 Latin American countries; negotiating additional territories
Continued transactions with largest shareholder Jeil Pharmaceutical (44.56%); related party disclosures
Shares outstanding 44,887,840 after 1:3 stock dividend (2025) and option exercises; share capital KRW 22.44B